Charles River conducts contract studies in transgenic R6/2 mice to test the efficacy of novel therapeutics for treating Huntington’s disease (HD). All studies can be customized according to client needs.
The transgenic R6/2 mouse [B6CBA-Tg(HDexon1)62Gpb/1J] is the most commonly used animal model of Huntington’s disease. The R6/2 mouse contains N-terminally truncated mutant Htt (mHtt) with CAG repeat expansion (~125 repeats) within the huntingtin gene exon 1. This model develops HD-like symptoms, including decreased body weight as well as motor and cognitive deficits, starting as early as 6-8 weeks of age. Survival is followed until 25 weeks of age.